Who
Douglas A. Treco
Director
Company insider
Files Form 4 as: Director, CRISPR Therapeutics AG; CEO & Chairman, Inozyme Pharma; President and CEO, Ra Pharmaceuticals.
In numbers
- Trades disclosed
- 44
- Buys
- 1
- Sells
- 2
- Bought
- $1.1M
- Sold
- $60K
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 1 Feb 2017
- Last trade
- 5 Jun 2026
- Last filed
- 9 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 9 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 6 Aug 2025filed 8 Aug 2025 | CRSP CRISPR Therapeutics AGGenomics & Gene Editing | SEC FORM 4 Bought | $1.1M20,000 at $57.03 | filing |
| 1 Jul 2025filed 3 Jul 2025 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code D | —150,000 | filing |
| 1 Jul 2025filed 3 Jul 2025 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code D | —86,979 | filing |
| 1 Jul 2025filed 3 Jul 2025 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code D | —400,000 | filing |
| 1 Jul 2025filed 3 Jul 2025 | Inozyme Pharma | SEC FORM 4 Code U | $175K43,861 at $4.00 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Inozyme Pharma | SEC FORM 4 Code A | $2,0832,815 at $0.74 | filing |
| 5 Jun 2025filed 6 Jun 2025 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 2 Apr 2025filed 3 Apr 2025 | Inozyme Pharma | SEC FORM 4 Sold | $7,8498,819 at $0.89 | filing |
| 1 Apr 2025filed 3 Apr 2025 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | Inozyme Pharma | SEC FORM 4 Code M | —25,000 | filing |
| 11 Mar 2025filed 17 Mar 2025 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 11 Mar 2025filed 17 Mar 2025 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 30 Sep 2024filed 3 Oct 2024 | Inozyme Pharma | SEC FORM 4 Code A | $7,6101,710 at $4.45 | filing |
| 30 May 2024filed 31 May 2024 | CRSP CRISPR Therapeutics AGoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 2 Apr 2024filed 3 Apr 2024 | Inozyme Pharma | SEC FORM 4 Sold | $52K7,523 at $6.94 | filing |
| 1 Apr 2024filed 3 Apr 2024 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 1 Apr 2024filed 3 Apr 2024 | Inozyme Pharma | SEC FORM 4 Code M | —25,000 | filing |
| 13 Mar 2024filed 15 Mar 2024 | Inozyme Pharmaoption or derivative | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
News
CRISPR Therapeutics Announces Chief Financial Officer TransitionCRSP · manilatimes.net · 19 Oct 2026Where Will CRISPR Therapeutics Stock Be in 2030?CRSP · aol.com · 18 Oct 2026Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.CRSP · aol.com · 18 Oct 2026
0 headlines in the last 90 days name Douglas A. Treco; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.